GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL is positioned for attractive fundamental upside because Galleri has strong clinical validation, including PATHFINDER 2’s 60% positive-predictive value, specificity of 99.6%, and Cancer Signal Origin accuracy above 90%, which supports differentiation in a large, underpenetrated MCED market. The bull case is further strengthened by the 14% reduction in Stage IV cancers in NHS-Galleri, improving confidence that the test can deliver meaningful clinical utility and become a gold-standard screening platform over time. Financially, total revenue grew 28% and Galleri MCED sales rose 37% in 1Q on 50% volume growth, while GRAIL ended 1Q with $823M in cash and 18.3K prescribers, giving it both operating momentum and balance-sheet support.

GRAIL is burdened by persistent net losses, heavy cash burn, and a commercialization model that remains far from self-funding, with total OpEx expected to stay materially above revenue for the next five years while financing needs persist. Its path to scale is constrained by lengthy and uncertain clinical studies, complex FDA review for an MCED test with no prior approval precedent, and limited reimbursement because Galleri lacks broad Medicare and government coverage despite private payer wins. Demand also appears structurally weaker than bulls assume: the $949 cash-pay price suppresses conversion, supplier concentration and royalty resumption in 2027 add cost pressure, and the company’s growth depends on sustaining expensive sales and marketing spend in a highly competitive market.